Kazia Therapeutics LtdNASDAQ:KZIA
- LAST PRICE5.2000
- TODAY'S CHANGE (%)-0.2600 (-4.7619%)
- Bid / Lots5.1800/ 5
- Ask / Lots5.3200/ 1
- Open / Previous Close5.6200 / 5.4600
- Day Range
- 52 Week Range
- Volume12,199
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KZIA |
|---|---|---|
| 09:32 ET | 501 | 5.62 |
| 09:35 ET | 300 | 5.4261 |
| 09:37 ET | 100 | 5.4314 |
| 09:42 ET | 339 | 5.41 |
| 09:46 ET | 2062 | 5.16 |
| 09:50 ET | 307 | 5.223 |
| 09:51 ET | 330 | 5.39 |
| 09:55 ET | 1000 | 5.3899 |
| 10:08 ET | 200 | 5.32 |
| 10:13 ET | 100 | 5.32 |
| 10:20 ET | 450 | 5.4048 |
| 10:22 ET | 300 | 5.75 |
| 10:24 ET | 1162 | 5.33 |
| 10:29 ET | 1170 | 5.33 |
| 10:31 ET | 938 | 5.32 |
| 10:36 ET | 582 | 5.32 |
| 10:47 ET | 750 | 5.2 |
Nov 4, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kazia Therapeutics Ltd | 18.2M | -0.1x | --- |
Cardio Diagnostics Holdings Inc | 12.2M | -0.8x | --- |
Protext Mobility Inc | 12.3M | 0.0x | --- |
Indaptus Therapeutics Inc | 12.4M | -0.6x | --- |
Imunon Inc | 12.4M | -0.4x | --- |
Biomx Inc | 10.9M | 2.6x | --- |
Company Information
Kazia Therapeutics Limited is an oncology focused drug development company. The Company is engaged in the pharmaceutical research and development. Its lead program includes Paxalisib and EVT801. Paxalisib is a small molecule inhibitor of the PI3K / Akt / mTOR pathway, a central regulator of growth and cell division that is dysregulated in many types of cancer. Paxalisib is being developed for several forms of brain cancer. EVT801 is a small molecule inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3), which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. EVT801 is an inhibitor of VEGFR3, a cellular receptor for VEGF. The Company’s drug candidates are designed to treat disease, such as brain cancer, renal cancer, and liver cancer.
Contact Information
- Headquarters
- Three International Towers Level 24 , 300 Barangaroo AvenueSYDNEY, NSW, Australia 2000
- Phone
- ---
- Fax
- ---
Executives
- Interim Executive Chairman of the Board, Chief Executive Officer, Managing Director
- John Friend
- Chief Financial Officer
- Karen Krumeich
- Clinical & Regulatory Affairs Manager
- Lilischkis Kimberley
- Chief Business Officer
- Peng Leong
- Program Director - Degenerative Diseases
- Stephen Palmer
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $18.2M |
|---|---|
Revenue (TTM) | $14.7K |
Shares Outstanding | 166.4K |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.00 |
EPS | $-80.67 |
Book Value | $34.34 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | 1,239.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -91,918.53% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
